GE invests $5M for cardiovascular genomic diagnostics
GE Healthcare and CardioDx, a cardiovascular genomic diagnostics company, have entered into a strategic alliance to co-develop diagnostic technologies to improve the care and management of patients with cardiovascular disease.

The GE Healthymagination Fund, a new equity fund that makes investments in healthcare technology companies, has invested $5 million in CardioDx as part of a series D round that the fund is leading. This marks the first investment for the Healthymagination Fund. Other financial terms were not disclosed.

The Palo Alto, Calif.-based CardioDx said it develops genomic tests to aid in the assessment and tailoring of care of individuals with cardiovascular diseases, such as coronary artery disease (CAD), cardiac arrhythmias and heart failure. Its initial product, Corus CAD, is a non-invasive genomic test that uses data such as gene expression levels and other patient characteristics to assess the likelihood that a patient has obstructive CAD.

This alliance reflects GE’s interest in opportunities to combine in vivo and in vitro diagnostic technologies to improve patient care, according to CardioDx.